{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.96","estimateComment":"Cox regression model with treatment as a covariate stratified by geographic region (Asia vs RoW)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.00894","pValueComment":"One-sided p-value based on stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.77","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"10.3","value":"8.2"},{"groupId":"OG001","lowerLimit":"6.1","upperLimit":"8.2","value":"7.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause. Median OS in participants with SCC of the esophagus is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg IV on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received Investigator's choice of paclitaxel 80-100 mg/m\\^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m\\^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m\\^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The efficacy analysis population consisted of all randomized participants with SCC of the esophagus. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Through Final Analysis data cutoff date of 15-Oct-2018 (up to approximately 34 months)","title":"Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus","type":"PRIMARY","unitOfMeasure":"Months"}